{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:01:00Z","timestamp":1792080060932,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The aim was to evaluate if bariatric surgery can affect the LT4 performance. The endpoints were the following: 1) difference between LT4 daily dose before and 1 year after surgery, 2) difference between LT4 dose per weight before and 1 year after surgery, 3) difference among LT4 preparations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study period was between January 2018 and May 2022. Inclusion criteria were a) adults undergone bariatric surgery, b) with proven autoimmune hypothyroidism, c) on LT4 therapy before bariatric surgery, d) using any commercialized LT4 preparation. Excluded were patients a) proven to have or suspected for pre-surgical intestinal malabsorption, b) with other potential interfering factors on LT4 absorption; c) with heart, renal, and\/or hepatic failure, d) with recent\/current infection\/inflammation, e) in pregnancy, f) with incomplete data about LT4 therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>According to the selection criteria, 40 patients were included. Both TSH and LT4 daily doses were not significantly different with respect to baseline values. On the contrary, the LT4 dose per weight was significantly increased, especially in RYGB patients. An increased LT4 dose per weight was observed with the reduction of weight.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>One year after bariatric surgery 1) the daily dose of LT4 remains unchanged, and 2) despite the significant weight reduction, LT4 dose per weight increases. Most data are referred to LT4 tablet and the performance of LT4 caps should be further investigated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-022-03289-0","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T19:02:45Z","timestamp":1672340565000},"page":"563-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The performance of levothyroxine tablet is impaired by bariatric surgery"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-4937","authenticated-orcid":false,"given":"Pierpaolo","family":"Trimboli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ossola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Quarenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Camponovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ruinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"12","key":"3289_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"J. Jonklaas, A.C. Bianco, A.J. Bauer et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid 24(12), 1670\u20131751 (2014). https:\/\/doi.org\/10.1089\/thy.2014.0028","journal-title":"Thyroid"},{"issue":"10","key":"3289_CR2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/jps.2600671030","volume":"67","author":"N Kitamori","year":"1978","unstructured":"N. Kitamori, K. Iga, Dissolution profiles of drugs from tablets. J. Pharm. Sci. 67(10), 1436\u20131439 (1978). https:\/\/doi.org\/10.1002\/jps.2600671030","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"3289_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/thy.1991.1.241","volume":"1","author":"MT Hays","year":"1991","unstructured":"M.T. Hays, Localization of human thyroxine absorption. Thyroid 1(3), 241\u2013248 (1991). https:\/\/doi.org\/10.1089\/thy.1991.1.241","journal-title":"Thyroid"},{"issue":"1","key":"3289_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1210\/er.2018-00168","volume":"40","author":"C Virili","year":"2019","unstructured":"C. Virili, A. Antonelli, M.G. Santaguida, S. Benvenga, M. Centanni, Gastrointestinal malabsorption of thyroxine. Endocr. Rev. 40(1), 118\u2013136 (2019). https:\/\/doi.org\/10.1210\/er.2018-00168","journal-title":"Endocr. Rev."},{"issue":"2","key":"3289_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12020-019-02185-4","volume":"67","author":"M Castellana","year":"2020","unstructured":"M. Castellana, C. Castellana, L. Giovanella, P. Trimboli, Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy. Endocrine 67(2), 281\u2013290 (2020). https:\/\/doi.org\/10.1007\/s12020-019-02185-4","journal-title":"Endocrine"},{"issue":"3","key":"3289_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s11695-018-3593-1","volume":"29","author":"R Welbourn","year":"2019","unstructured":"R. Welbourn, M. Hollyman, R. Kinsman et al. Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the fourth IFSO Global Registry Report 2018. Obes. Surg. 29(3), 782\u2013795 (2019). https:\/\/doi.org\/10.1007\/s11695-018-3593-1","journal-title":"Obes. Surg."},{"issue":"2","key":"3289_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1210\/er.2017-00253","volume":"39","author":"GA Bray","year":"2018","unstructured":"G.A. Bray, W.E. Heisel, A. Afshin et al. The science of obesity management: an endocrine society scientific statement. Endocr. Rev. 39(2), 79\u2013132 (2018). https:\/\/doi.org\/10.1210\/er.2017-00253","journal-title":"Endocr. Rev."},{"issue":"10","key":"3289_CR8","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1007\/s11695-016-2314-x","volume":"26","author":"S Gadiraju","year":"2016","unstructured":"S. Gadiraju, C.J. Lee, D.S. Cooper, Levothyroxine dosing following bariatric surgery. Obes. Surg. 26(10), 2538\u20132542 (2016). https:\/\/doi.org\/10.1007\/s11695-016-2314-x","journal-title":"Obes. Surg."},{"issue":"6","key":"3289_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.soard.2021.02.028","volume":"17","author":"C Azran","year":"2021","unstructured":"C. Azran, N. Hanhan-Shamshoum, T. Irshied et al. Hypothyroidism and levothyroxine therapy following bariatric surgery: a systematic review, meta-analysis, network meta-analysis, and meta-regression. Surg. Obes. Relat. Dis. 17(6), 1206\u20131217 (2021). https:\/\/doi.org\/10.1016\/j.soard.2021.02.028","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"1","key":"3289_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11695-016-2247-4","volume":"27","author":"P Fallahi","year":"2017","unstructured":"P. Fallahi, S.M. Ferrari, S. Camastra et al. TSH normalization in bariatric surgery patients after the switch from L-thyroxine in tablet to an oral liquid formulation. Obes. Surg. 27(1), 78\u201382 (2017). https:\/\/doi.org\/10.1007\/s11695-016-2247-4","journal-title":"Obes. Surg."},{"issue":"9","key":"3289_CR11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s11695-013-1015-y","volume":"23","author":"I Pirola","year":"2013","unstructured":"I. Pirola, A.M. Formenti, E. Gandossi et al. Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes. Surg. 23(9), 1493\u20131496 (2013). https:\/\/doi.org\/10.1007\/s11695-013-1015-y","journal-title":"Obes. Surg."},{"issue":"3","key":"3289_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.soard.2015.02.003","volume":"11","author":"SA Brethauer","year":"2015","unstructured":"S.A. Brethauer, J. Kim, M. el Chaar et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg. Obes. Relat. Dis. 11(3), 489\u2013506 (2015). https:\/\/doi.org\/10.1016\/j.soard.2015.02.003","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"5","key":"3289_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.soard.2012.07.018","volume":"9","author":"A S\u00e1nchez-Pernaute","year":"2013","unstructured":"A. S\u00e1nchez-Pernaute, M.\u00c1. Rubio, E. P\u00e9rez Aguirre, A. Barabash, L. Cabrerizo, A. Torres, Single-anastomosis duodenoileal bypass with sleeve gastrectomy: metabolic improvement and weight loss in first 100 patients. Surg. Obes. Relat. Dis. 9(5), 731\u2013735 (2013). https:\/\/doi.org\/10.1016\/j.soard.2012.07.018","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"5","key":"3289_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.soard.2018.01.004","volume":"14","author":"S Ghiassi","year":"2018","unstructured":"S. Ghiassi, K. Higa, S. Chang et al. Conversion of standard Roux-en-Y gastric bypass to distal bypass for weight loss failure and metabolic syndrome: 3-year follow-up and evolution of technique to reduce nutritional complications. Surg. Obes. Relat. Dis. 14(5), 554\u2013561 (2018). https:\/\/doi.org\/10.1016\/j.soard.2018.01.004","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"3","key":"3289_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000499385","volume":"12","author":"H Yu","year":"2019","unstructured":"H. Yu, Q. Li, M. Zhang et al. Decreased leptin is associated with alterations in thyroid-stimulating hormone levels after Roux-en-Y gastric bypass surgery in obese euthyroid patients with type 2 diabetes. Obes. Facts 12(3), 272\u2013280 (2019). https:\/\/doi.org\/10.1159\/000499385","journal-title":"Obes. Facts"},{"issue":"1","key":"3289_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1210\/jc.2004-1306","volume":"90","author":"F Santini","year":"2005","unstructured":"F. Santini, A. Pinchera, A. Marsili et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90(1), 124\u2013127 (2005). https:\/\/doi.org\/10.1210\/jc.2004-1306","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"3289_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1089\/thy.2015.0473","volume":"26","author":"P Fierabracci","year":"2016","unstructured":"P. Fierabracci, S. Martinelli, A. Tamberi et al. Weight loss and variation of levothyroxine requirements in hypothyroid obese patients after bariatric surgery. Thyroid 26(4), 499\u2013503 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0473","journal-title":"Thyroid"},{"issue":"3","key":"3289_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/thy.1991.1.241","volume":"1","author":"MT Hays","year":"1991","unstructured":"M.T. Hays, Localization of human thyroxine absorption. Thyroid 1(3), 241\u2013248 (1991). https:\/\/doi.org\/10.1089\/thy.1991.1.241","journal-title":"Thyroid"},{"issue":"6","key":"3289_CR19","doi-asserted-by":"publisher","first-page":"941","DOI":"10.7326\/0003-4819-90-6-941","volume":"90","author":"F Azizi","year":"1979","unstructured":"F. Azizi, R. Belur, J. Albano, Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Ann. Intern. Med. 90(6), 941\u2013942 (1979). https:\/\/doi.org\/10.7326\/0003-4819-90-6-941","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"3289_CR20","first-page":"245","volume":"10","author":"JS Bevan","year":"1986","unstructured":"J.S. Bevan, J.F. Munro, Thyroxine malabsorption following intestinal bypass surgery. Int. J. Obes. 10(3), 245\u2013246 (1986)","journal-title":"Int. J. Obes."},{"issue":"8","key":"3289_CR21","first-page":"765","volume":"123","author":"DJ Topliss","year":"1980","unstructured":"D.J. Topliss, J.A. Wright, R. Volp\u00e9, Increased requirement for thyroid hormone after a jejunoileal bypass operation. Can. Med. Assoc. J. 123(8), 765\u2013766 (1980)","journal-title":"Can. Med. Assoc. J."},{"key":"3289_CR22","doi-asserted-by":"publisher","first-page":"621616","DOI":"10.3389\/fendo.2020.621616","volume":"11","author":"C Virili","year":"2021","unstructured":"C. Virili, N. Brusca, S. Capriello, M. Centanni, Levothyroxine therapy in gastric malabsorptive disorders. Front Endocrinol. 11, 621616 (2021). https:\/\/doi.org\/10.3389\/fendo.2020.621616.","journal-title":"Front Endocrinol."},{"issue":"1","key":"3289_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12020-019-02049-x","volume":"66","author":"C Virili","year":"2019","unstructured":"C. Virili, P. Trimboli, M. Centanni, Novel thyroxine formulations: a further step toward precision medicine. Endocrine 66(1), 87\u201394 (2019). https:\/\/doi.org\/10.1007\/s12020-019-02049-x","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03289-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T07:20:30Z","timestamp":1684567230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03289-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["3289"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03289-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"P.T. serves as consultant and member of advisory board of IBSA but the content of this paper has not been conditioned by his role. L.R. received honorarium from IBSA as speaker. The other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by Tessin Ethical Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all subjects involved in the study according to the Ethics Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}